OPEN END TURBO LONG - ELI LILLY & CO | Real-time Bid/Ask 07:47:11 12/07/2024 BST | ||
| 55.67 EUR / 55.91 EUR | +0.78% |
|
| Current month | +1.47% | ||
| 1 month | +5.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 11/07/24 | 55.36 | -2.40% |
| 10/07/24 | 56.72 | +1.11% |
| 09/07/24 | 56.1 | +2.86% |
| 08/07/24 | 54.54 | +0.53% |
| 05/07/24 | 54.25 | +2.17% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 08:05 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MD6Z9T |
| ISIN | DE000MD6Z9T9 |
| Date issued | 11/08/2022 |
| Strike | 327.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 56.81 € |
|---|---|
| Lowest since issue | 1.61 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Certificates
- Certificat
